Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
Publication in refereed journal


香港中文大学研究人员 ( 现职)

莫树锦教授 (肿瘤学系)

全文

数位物件识别号 (DOI) http://dx.doi.org/10.1097/JTO.0000000000000693

引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/7WOS source URL

其它资讯

摘要Introduction: Sorafenib monotherapy has shown benefits in phase II trials as third-/fourth-line treatment in patients with non-small-cell lung cancer (NSCLC).

着者Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JCH, Wakelee HA, Seto T, Wu YL, Novello S, Juhasz E, Aren O, Sun Y, Schmelter T, Ong TJ, Pena C, Smit EF, Mok TS
期刊名称Journal of Thoracic Oncology
出版年份2015
月份12
日期1
卷号10
期次12
出版社LIPPINCOTT WILLIAMS & WILKINS
页次1http://aims.cuhk.edu.hk/converis/portal/Publication/745 - 1http://aims.cuhk.edu.hk/converis/portal/Publication/753
国际标準期刊号1556-0864
电子国际标準期刊号1556-1380
语言英式英语

关键词EGFR mutation; KRAS mutation; Molecular targeted therapy; Non-small-cell lung cancer; Sorafenib
Web of Science 学科类别Oncology; Respiratory System